Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Rheumatology
•
Vasculitis
•
Primary Care
When advising patients on starting Avacopan for Granulomatosis with polyangiitis, what side effects do you tell patients are commonly seen in clinical practice?
Related Questions
How would you manage active psoriasis and psoriatic arthritis in patient on Rituximab and prednisone for MPO positive vasculitis?
How long after parathyroidectomy (for parathyroid adenoma with hyperparathyroidism) do you wait before initiating romosuzumab in an older patient with osteoporosis and very high fracture risk?
How do you determine duration of therapy for patients who have responded well to voclosporin therapy?
What is your approach for severe SCLE in patients unable to tolerate HCQ?
Would you continue Forteo treatment past the recommended 2 years if T scores remain low and procollagen (P1NP) is elevated and if so, how would you monitor response?
How do you approach medication management in patients with RA when transitioning from csDMARD triple therapy to anti-TNF?
How do you approach management of osteoporosis in patients post lung transplant?
When do you consider Mesna for patients taking oral cyclophosphamide?
How would you approach the workup and management of isolated inflammatory subglottic stenosis in a young previously healthy patient that is steroid responsive with a completely negative serologic autoimmune workup?
Should HCQ be continued in an asymptomatic SLE patient who has received renal transplant?
